Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Sodium Sulfate, Magnesium Sulfate, And Potassium Chloride
Brand Name
Sutab
Generic Name
Sodium Sulfate, Magnesium Sulfate, And Potassium Chloride
Active Ingredient
Magnesium Sulfate AnhydrousCategory
Other
Variants
1
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 2.7 g/1 | TABLET | ORAL | 52268-201 |
Detailed information about Sutab
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Sutab, you must consult a qualified healthcare professional.
Magnesium Sulfate Anhydrous is a potent inorganic salt used primarily as an electrolyte replenisher and anticonvulsant. It plays a critical role in managing magnesium deficiency, pre-eclampsia, and certain cardiac arrhythmias within clinical settings.
Dosage for Magnesium Sulfate Anhydrous must be highly individualized based on the patient's clinical status, serum magnesium levels, and renal function. Standard ranges include:
Pediatric dosing is strictly weight-based and must be calculated with extreme caution:
Since magnesium is excreted almost entirely by the kidneys, patients with renal impairment are at high risk for magnesium toxicity. For patients with a Creatinine Clearance (CrCl) less than 30 mL/min, the dose should be reduced by 50%, and serum magnesium levels must be monitored every 4 to 6 hours.
No specific dose adjustments are required for patients with liver disease, as magnesium does not undergo hepatic metabolism. However, these patients often have concurrent electrolyte imbalances that require careful monitoring.
Geriatric patients often have undiagnosed reductions in renal function. Dosing should start at the lower end of the range, with frequent monitoring of renal function and clinical signs of toxicity (e.g., deep tendon reflexes).
Magnesium Sulfate Anhydrous is almost exclusively administered by healthcare professionals in a hospital or clinical setting.
In a clinical setting, magnesium sulfate is usually given on a strict schedule or as a continuous infusion. If a dose is missed, it should be administered as soon as possible. However, if it is almost time for the next dose, the missed dose should be skipped to avoid the risk of toxicity. Do not double the dose.
Magnesium overdose (hypermagnesemia) is a medical emergency. Signs include:
Emergency Measures: The immediate treatment for magnesium toxicity is the intravenous administration of Calcium Gluconate (10% solution, 10-20 mL), which acts as a direct antagonist to the effects of magnesium. In cases of severe renal failure, hemodialysis may be required to remove magnesium from the blood.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or administration rate without medical guidance. Continuous monitoring is required during high-dose therapy.
Most common side effects of Magnesium Sulfate Anhydrous are related to its vasodilatory effects and its impact on the central nervous system. These include:
> Warning: Stop taking Magnesium Sulfate Anhydrous and call your doctor immediately if you experience any of these serious symptoms. These are often signs of magnesium toxicity.
Magnesium Sulfate Anhydrous is typically used for short-term acute management (24 to 48 hours). However, prolonged use (especially in pregnant women for more than 5-7 days) can lead to:
There is no standard FDA Black Box Warning for Magnesium Sulfate Anhydrous; however, the FDA issued a Drug Safety Communication in 2013 warning against the off-label use of magnesium sulfate injection for more than 5-7 days in pregnant women to stop preterm labor. This use is not FDA-approved and can lead to low calcium levels and bone changes (osteopenia and fractures) in the developing baby. The drug is officially classified as Pregnancy Category D when used for this specific, prolonged off-label indication.
Report any unusual symptoms or persistent side effects to your healthcare provider immediately. Monitoring of serum magnesium levels is the most effective way to prevent these adverse events.
Magnesium Sulfate Anhydrous must be administered with extreme caution. Because it affects the central nervous system and muscle function, it can mask other clinical symptoms or worsen underlying neurological conditions. Patients receiving this medication require constant clinical observation, including monitoring of vital signs, oxygen saturation, and neurological reflexes.
No FDA black box warnings are currently issued for Magnesium Sulfate Anhydrous. However, clinicians must adhere to the 2013 FDA safety mandate regarding the limitation of use in preterm labor to less than 7 days to prevent fetal bone toxicity.
To ensure safety, the following parameters must be monitored:
Magnesium sulfate causes significant central nervous system depression, drowsiness, and blurred vision. Patients should not drive, operate heavy machinery, or engage in hazardous activities until the medication has completely cleared their system and they have been cleared by a physician.
Alcohol should be strictly avoided. Alcohol can increase the magnesium-depleting effects of the kidneys in the long term, but in the acute phase, it can synergistically increase the CNS depressant effects of magnesium sulfate, leading to dangerous levels of sedation and respiratory depression.
When discontinuing a high-dose infusion (e.g., after 24 hours postpartum in eclampsia), the drug is typically stopped abruptly without a taper, provided the patient's clinical status has stabilized. However, the patient must be monitored for several hours after discontinuation for any rebound symptoms or delayed toxicity.
> Important: Discuss all your medical conditions, especially kidney disease and neuromuscular disorders, with your healthcare provider before starting Magnesium Sulfate Anhydrous.
Most interactions with Magnesium Sulfate Anhydrous occur through pharmacodynamic mechanisms—meaning the drugs have additive or opposing effects on the same physiological systems (like the neuromuscular junction or the heart's electrical system). It does not significantly interact with the Cytochrome P450 (CYP) enzyme system, which is the primary pathway for many drug-drug interactions in the liver.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter antacids or laxatives that may contain additional magnesium.
Magnesium Sulfate Anhydrous must NEVER be used in the following conditions:
Conditions requiring a careful risk-benefit analysis include:
There are no known cross-sensitivities between Magnesium Sulfate Anhydrous and other drug classes. However, patients who have had a previous hypersensitivity reaction to any magnesium salt should not receive the anhydrous form.
> Important: Your healthcare provider will evaluate your complete medical history, including your kidney function and heart rhythm, before prescribing Magnesium Sulfate Anhydrous.
FDA Pregnancy Category: Magnesium sulfate is generally considered safe for the short-term (under 48 hours) prevention of eclampsia. However, for the prolonged treatment of preterm labor (tocolysis), it is categorized as Category D.
Magnesium sulfate is excreted in breast milk. However, when used for short periods (24-48 hours), it is generally considered compatible with breastfeeding. The amount of magnesium absorbed by the infant is typically negligible, and the American Academy of Pediatrics considers it usually safe. Healthcare providers should monitor the infant for signs of drowsiness or poor feeding.
Magnesium sulfate is approved for use in children for the treatment of hypomagnesemia and acute nephritis. It must be dosed strictly by weight (mg/kg). Children are particularly sensitive to the pain of IM injections, so solutions should be diluted. Safety and efficacy for other uses (like asthma) are supported by clinical guidelines but are technically off-label.
Elderly patients are at a higher risk for magnesium toxicity due to the natural age-related decline in kidney function. Clinical monitoring should be more frequent, and initial doses should be conservative. There is also an increased risk of falls due to the muscle-weakening and sedative effects of the drug.
This is the most critical special population. In patients with a Creatinine Clearance < 30 mL/min, the kidneys cannot clear magnesium effectively. Dosage must be reduced by at least 50%. Serum magnesium levels must be checked every 4-6 hours to ensure they remain within the therapeutic window (4-7 mEq/L).
No dosage adjustment is typically required for patients with liver disease. However, clinicians should be aware that patients with cirrhosis may have underlying electrolyte disturbances (like low potassium) that can be exacerbated by magnesium therapy.
> Important: Special populations require individualized medical assessment and more frequent laboratory monitoring to ensure safety.
Magnesium Sulfate Anhydrous acts as a pharmacological calcium antagonist. It competes with calcium at the voltage-gated calcium channels. By preventing calcium influx into the presynaptic nerve terminals, it inhibits the release of excitatory neurotransmitters like acetylcholine and glutamate. In the brain, magnesium acts as a non-competitive antagonist at the NMDA receptor, which prevents the neuronal over-excitation that leads to seizures. In vascular smooth muscle, the reduction in calcium entry leads to relaxation of the blood vessels, resulting in decreased blood pressure and improved blood flow.
| Parameter | Value |
|---|---|
| Bioavailability | 100% (IV), ~30-40% (Oral) |
| Protein Binding | ~30% (primarily to Albumin) |
| Half-life | 4-6 hours (Normal Renal Function) |
| Tmax | Immediate (IV), 1 hour (IM) |
| Metabolism | None (Inorganic Ion) |
| Excretion | Renal (90-100% of absorbed dose) |
Magnesium Sulfate Anhydrous is classified as an Electrolyte Replenisher and an Anticonvulsant. It is often grouped with other mineral salts but has unique properties as a CNS depressant and calcium antagonist that distinguish it from simple nutritional supplements.
Common questions about Sutab
Magnesium Sulfate Anhydrous is primarily used as an intravenous or intramuscular medication to treat severe magnesium deficiency and to prevent seizures in pregnant women with pre-eclampsia or eclampsia. It is also a critical treatment for a specific life-threatening heart rhythm called Torsades de Pointes. In some emergency settings, it is used off-label to help open the airways in patients with severe asthma who do not respond to standard treatments. Because it acts as a muscle relaxant and calcium blocker, it is highly effective in these acute, high-stakes clinical scenarios. It is almost always administered in a hospital setting under close medical supervision.
The most common side effects include a sudden feeling of warmth or flushing, increased sweating, and a mild drop in blood pressure. Many patients also report feeling thirsty or experiencing pain and redness at the site of the injection or IV. Because the medication slows down nerve and muscle activity, drowsiness and a feeling of general weakness are also very common. These effects are usually temporary and occur shortly after the infusion begins. However, if these symptoms become severe, it may indicate that the dose needs to be adjusted by the healthcare team.
No, you should not drink alcohol while being treated with Magnesium Sulfate Anhydrous. Alcohol is a central nervous system depressant, and when combined with magnesium sulfate, it can lead to dangerous levels of sedation and potentially life-threatening respiratory depression (slowed breathing). Furthermore, chronic alcohol use is a leading cause of magnesium deficiency because it causes the kidneys to flush magnesium out of the body. Combining the two can make it much harder for your doctor to stabilize your electrolyte levels. Always wait until the medication has completely left your system and your doctor has given you the clear before consuming alcohol.
Magnesium sulfate is the standard, life-saving treatment for preventing seizures in pre-eclampsia, and for this short-term use (usually 24-48 hours), it is considered safe and necessary. However, the FDA warns against using it for more than 5 to 7 days to stop preterm labor, as prolonged exposure can cause low calcium and bone problems in the developing fetus. When used appropriately for eclampsia, the benefits to both the mother and the baby far outweigh the risks. Your obstetrician will carefully monitor both you and your baby's heart rate during the infusion. It is classified as Pregnancy Category D only for prolonged, off-label use in preterm labor.
The onset of action depends on how the medication is administered. When given intravenously (IV), the effects are almost immediate, which is why it is used in emergencies like cardiac arrest or active seizures. When given as an intramuscular (IM) injection, it typically takes about 30 to 60 minutes to reach effective levels in the bloodstream. The duration of the effect is also relatively short, lasting about 30 minutes for IV and up to 4 hours for IM, which is why it is often given as a continuous slow drip (infusion) to maintain steady levels in the body.
In most clinical cases, such as after a 24-hour post-delivery period for eclampsia, the infusion is stopped all at once without a gradual tapering process. This is safe because the body naturally clears the excess magnesium through the kidneys over the following several hours. However, this decision is always made by a physician based on your blood work and clinical stability. You should never attempt to stop or alter an infusion yourself. After the medication is stopped, your medical team will continue to monitor your reflexes and magnesium levels to ensure they return to a normal range safely.
Because this medication is usually administered by nurses in a hospital setting, a missed dose is rare. However, if you are on a scheduled injection plan and a dose is missed, it should be given as soon as possible. If it is almost time for your next scheduled dose, the missed dose should be skipped to prevent the risk of magnesium toxicity. You should never receive a double dose to make up for a missed one. Inform your healthcare provider immediately if you believe a dose was missed or if the IV pump has stopped working.
No, Magnesium Sulfate Anhydrous does not cause weight gain. It is typically used for short-term, acute medical treatments lasting only a few days, which is not long enough to affect body fat or muscle mass. Some patients might experience temporary fluid retention or swelling (edema) due to the underlying condition being treated, such as pre-eclampsia or kidney issues, but this is not a direct result of the magnesium itself. In fact, magnesium sulfate can sometimes have a mild diuretic effect as the kidneys work to excrete the salt. Any significant changes in weight should be discussed with your doctor.
Magnesium sulfate has several significant drug interactions that your doctor must manage. It can dangerously increase the effects of blood pressure medications (calcium channel blockers) and muscle relaxants used during surgery. It also interacts with certain antibiotics like gentamicin, increasing the risk of breathing problems. Because of these risks, it is vital that you provide your healthcare team with a complete list of all medications, vitamins, and herbal supplements you are taking. Your doctor may need to adjust your other dosages while you are receiving magnesium therapy.
Yes, Magnesium Sulfate is widely available as a generic medication and is produced by numerous pharmaceutical manufacturers. It is a very low-cost, essential medicine that is a staple in almost every hospital's emergency and labor and delivery departments. Because it is an inorganic salt rather than a complex synthetic drug, there is no 'brand name' version that is superior to the generic. The anhydrous form is a specific chemical state used in manufacturing, but the resulting injectable solutions are standardized for clinical use across the industry.
Other drugs with the same active ingredient (Magnesium Sulfate Anhydrous)